000720989 000__ 05353cam\a2200505\i\4500
000720989 001__ 720989
000720989 005__ 20210515103400.0
000720989 006__ m\\\\\o\\d\\\\\\\\
000720989 007__ cr\cn\nnnunnun
000720989 008__ 130605t20122012dcua\\\\ob\\\\100\0\eng\d
000720989 020__ $$z9780309260244
000720989 020__ $$z0309260248
000720989 020__ $$z9780309260213
000720989 020__ $$a9780309260251$$qelectronic book
000720989 035__ $$a(CaPaEBR)ebr10863895
000720989 035__ $$a(OCoLC)817900348
000720989 040__ $$aCaPaEBR$$beng$$erda$$epn$$cCaPaEBR
000720989 043__ $$an-us---
000720989 05014 $$aRS420$$b.G4 2012eb
000720989 08204 $$a615.1$$223
000720989 24500 $$aGenome-based therapeutics$$h[electronic resource] :$$btargeted drug discovery and development : workshop summary /$$cAdam C. Berger and Steve Olson, Rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
000720989 24630 $$aTargeted drug discovery and development
000720989 264_1 $$aWashington, District of Columbia :$$bNational Academies Press,$$c[2012]
000720989 264_4 $$c©2012
000720989 300__ $$a1 online resource (109 pages) :$$billustrations
000720989 336__ $$atext$$2rdacontent
000720989 337__ $$acomputer$$2rdamedia
000720989 338__ $$aonline resource$$2rdacarrier
000720989 504__ $$aIncludes bibliographical references (pages 55-57).
000720989 5050_ $$aIntroduction -- The current landscape -- Case studies: The development of Crizotinib for treatment of non-small-cell lung cancer; Use of genetics to inform drug development for the treatment of schizophrenia; A genetic approach to the treatment of cystic fibrosis -- Emerging technologies in drug development: Large-scale whole-genome sequencing; The value of clinical next-generation sequencing to drug developers; The uses of genomic information -- Evolving paradigms: Foundations and drug development: an example; Genomics and regulatory science; Pharmacy benefit management and pharmacogenomics; Repurposing of drugs -- Forging collaborative strategies for the development of personalized medicine:  The need for collaboration; FDA initiatives; NCATS initiatives; Biospecimens and databases; Reducing health disparities; Patient and physican education; An emphasis on the science.
000720989 506__ $$aAccess limited to authorized users.
000720989 520__ $$a"The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-based therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New paradigms in drug discovery: how genomic data are being used to revolutionize the drug discovery and development process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead"--Publisher's description.
000720989 588__ $$aDescription based on print version record.
000720989 650_0 $$aDrugs$$zUnited States$$xDesign$$vCongresses.
000720989 650_0 $$aPharmaceutical technology$$zUnited States$$vCongresses.
000720989 650_0 $$aPharmaceutical industry$$zUnited States$$vCongresses.
000720989 650_0 $$aGenomics$$zUnited States$$vCongresses.
000720989 7001_ $$aBerger, Adam C.,$$econtributor.
000720989 7001_ $$aOlson, Steve,$$d1956-$$econtributor.
000720989 7102_ $$aInstitute of Medicine (U.S.).$$bRoundtable on Translating Genomic-Based Research for Health,$$eissuing body.
000720989 7102_ $$aInstitute of Medicine (U.S.).$$bBoard on Health Sciences Policy,$$eissuing body.
000720989 77608 $$iPrint version:$$tGenome-based therapeutics : targeted drug discovery and development : workshop summary.$$dWashington, District of Columbia : National Academies Press, [2012]$$z9780309260213$$w(OCoLC)824457733$$w(DLC)  2012554410
000720989 852__ $$bebk
000720989 85640 $$3ProQuest Ebook Central Academic Complete$$uhttps://univsouthin.idm.oclc.org/login?url=http://site.ebrary.com/lib/usiricelib/Doc?id=10863895$$zOnline Access
000720989 909CO $$ooai:library.usi.edu:720989$$pGLOBAL_SET
000720989 980__ $$aEBOOK
000720989 980__ $$aBIB
000720989 982__ $$aEbook
000720989 983__ $$aOnline